Skip to main content
Retour
Watch Compare

Rani Therapeutics Holdings, Inc.

Qualité des données : 100%
RANI
NASDAQ Manufacturing Chemicals
0,74 €
▼ 0,04 € (-4,76%)
Cap. Boursière: 77,30 M
Prix
0,78 €
Cap. Boursière
77,30 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue declined -11,95% annually over 5 years
Negative free cash flow of -18,80 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 70,80%
Capital efficient — spends only 5,39% of revenue on capex

Croissance

Revenue Growth (5Y)
-11,95%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)58,85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-1817,09%
Op. Margin-2345,99%

Sécurité

Debt / Equity
N/A
Current Ratio0,26
Interest Coverage-13,25

Valorisation

PE (TTM|NTM)
-2,61 | -3,61
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -2,6 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % -1817,1 -41,5
Rev Growth 5Y % -12,0 1,8
D/E — 0,3

Objectif de Cours des Analystes

4 analystes
Buy
Actuel
0,74 €
+845.9%
Objectif
7,00 €
5,00 €
6,00 €
11,00 €
Prévisions
P/E Prévisionnel -3,61
BPA Prévisionnel -0,21 €
CA Est. 11,26 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,21 €
-0,24 € – -0,17 €
 11,26 M 4
FY2026 -0,24 €
-0,30 € – -0,19 €
 2,67 M 3

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,07 € -0,07 € -5,0%
Q32025 -0,12 € -0,12 € +2,7%
Q22025 -0,20 € -0,18 € +7,7%
Q12025 -0,24 € -0,22 € +8,3%

ETFs Holding This Stock

BRSIX BRSIX
0,06% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 58,85% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -11,95% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,63 M Net Income (TTM) -29,67 M
ROE N/A ROA -219,50%
Gross Margin N/A Operating Margin -2345,99%
Net Margin -1817,09% Free Cash Flow (TTM) -18,80 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,26
Interest Coverage -13,25 Asset Turnover 0,12
Working Capital -14,19 M Tangible Book Value -7,86 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,61 Forward P/E -3,61
P/B Ratio N/A P/S Ratio 47,34
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 6,86 Fwd Earnings Yield N/A
FCF Yield -24,32%
Market Cap 77,30 M Enterprise Value 86,91 M
Per Share
EPS (Diluted TTM) -0,45 Revenue / Share 0,02
FCF / Share -0,19 OCF / Share -0,19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 5,39% FCF Conversion 63,36%
SBC-Adj. FCF -32,40 M Growth Momentum 70,80

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,63 M 1,03 M — 0,0 2,72 M
Net Income -29,67 M -30,02 M -33,97 M -30,59 M -8,33 M
EPS (Diluted) -0,45 -1,05 -1,33 -1,28 —
Gross Profit — — — — —
Operating Income -38,31 M -53,31 M -66,10 M -63,45 M -51,60 M
EBITDA — — — — —
R&D Expenses 20,21 M 26,68 M 39,62 M 36,61 M 26,48 M
SG&A Expenses — — — — —
D&A 900 000,0 1,03 M 822 000,0 548 000,0 —
Interest Expense 2,89 M 5,03 M 5,09 M 1,07 M 466 000,0
Income Tax 0,0 0,0 0,0 70 000,0 41 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 58,62 M 36,63 M 57,92 M 108,03 M 124,21 M
Total Liabilities 17,11 M 33,14 M 32,47 M 34,02 M 2,64 M
Shareholders' Equity 33,01 M 1,99 M 12,87 M 36,86 M 47,41 M
Total Debt 0,0 25,00 M 30,00 M 30,00 M 2,41 M
Cash & Equivalents 18,62 M 3,76 M 5,86 M 27,01 M 117,45 M
Current Assets 53,32 M 29,74 M 50,85 M 100,92 M 119,60 M
Current Liabilities 12,67 M 19,89 M 7,99 M 4,82 M 2,64 M